These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Ito T; Ikeda H; Kamura H; Motohashi I; Kimura Y; Komino M; Arai H; Kuwamitsu O; Akuzawa N; Sando E; Morikawa T; Imura H; Inoue H; Hayakawa T; Teshigahara O; Ohara Y; Suzuki M; Morimoto K Expert Rev Vaccines; 2023; 22(1):288-298. PubMed ID: 36883371 [TBL] [Abstract][Full Text] [Related]
6. Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. Ito K; Piantham C; Nishiura H Euro Surveill; 2021 Jul; 26(27):. PubMed ID: 34240695 [TBL] [Abstract][Full Text] [Related]
7. Association of wastewater SARS-CoV-2 load with confirmed COVID-19 cases at a university hospital in Sapporo, Japan during the period from February 2021 to February 2023. Kagami K; Kitajima M; Takahashi H; Teshima T; Ishiguro N Sci Total Environ; 2023 Nov; 899():165457. PubMed ID: 37499823 [TBL] [Abstract][Full Text] [Related]
8. Letter from Japan. ; ; . PubMed ID: 33289211 [No Abstract] [Full Text] [Related]